Shots:

• Eli Lilly reported that first patients have been dosed in a P-I study of LY-CoV555- the first Ab emerge from the collaboration b/w Lilly & AbCellera to create Ab therapies against COVID-19. The P-I J2W-MC-PYAA study aims to evaluate the safety- tolerability- PK/PD of LY-CoV555 following a single dose administered to participants hospitalized for COVID-19
• Post-P-I results- Lilly anticipates the assessment of LY-CoV555 in non-hospitalized COVID-19 patients.  The company plans to study the drug in a preventative setting- focusing on vulnerable patient populations who are not optimal candidates for vaccines
• In the month-end- Lilly will review the results of the P-I J2W-MC-PYAA study and intend to initiate broader efficacy trials. Lilly plans to make several thousand doses of LY-CoV555 by the end of the year

Click here ­to­ read full press release/ article 

Ref: Eli Lilly | Image: Eli Lilly